Mavrilimumab

Mavrilimumab

Phase 2

Photo of scientists working in laboratory

Rationale

We believe that by blocking GM-CSF signaling, mavrilimumab may be able to reverse the course of GCA by upstream targeting of the cell types driving the inflammatory process, a mechanism that is different from currently available therapies.

  • The GM-CSF signaling pathway has been shown to be upregulated in GCA biopsies versus control at both the messenger ribonucleic acid (mRNA) and protein level.
  • Mavrilimumab reduced inflammatory molecules characteristic of GCA pathophysiology in an ex vivo GCA artery culture model.
  • Mavrilimumab reduced arterial inflammation compared to control in an in vivo model of vasculitis.
  • In previous Phase 2b trials in rheumatoid arthritis, mavrilimumab demonstrated rapid and prolonged reductions in interleukin-6 (IL-6) production, which is indicative of suppression of tissue inflammation upstream.

Status

We reported data from a randomized, double-blind, placebo-controlled Phase 2 clinical trial of mavrilimumab in GCA.

The Phase 2 trial randomized 70 patients 3:2 to mavrilimumab 150 mg (N=42) or placebo (N=28) biweekly injected subcutaneously, co-administered with a protocol-defined 26-week oral corticosteroid taper. Patients were stratified by new onset (n=35) or relapsing/refractory (n=35) disease.

The primary efficacy endpoint of time-to-first adjudicated GCA flare by Week 26 in all treated patients was statistically significant (Hazard Ratio = 0.38, p=0.0263). There was a 62% lower risk of flare in mavrilimumab recipients compared to placebo recipients.

The secondary efficacy endpoint of sustained remission at Week 26 in all treated patients was also statistically significant. The sustained remission rate was a 33.3 percentage points higher in mavrilimumab recipients (83.2%) compared to placebo recipients (49.9%) (p=0.0038).

While the study was not powered for disease cohorts, there was a consistent trend of efficacy across the new onset and relapsing/refractory cohorts.

Mavrilimumab was well-tolerated; there were no drug-related serious adverse events, and the rates of drug-related treatment-emergent adverse events between mavrilimumab recipients and placebo recipients were similar.

A 12-week washout safety follow-up period is ongoing, and additional analyses of this Phase 2 trial are planned.

Kiniksa expects to provide next steps for mavrilimumab, including for giant cell arteritis (GCA), in the first half of 2021.

COVID-19 Pneumonia and Hyperinflammation

In the Phase 2 portion of a Phase 2/3 trial of mavrilumuab in severe COVID-19, a 116 non-mechanically ventilated patients were randomized in a 1:1:1 ratio to receive a single intravenous (IV) dose of mavrilimumab 10 mg/kg, 6 mg/kg or placebo. Data showed that patients treated with mavrilimumab demonstrated a reduction in mechanical ventilation and death at Day 29 pooled across dose levels. Clinical improvement was observed on top of steroids and/or antivirals. Mavrilimumab was well-tolerated and exhibited a favorable safety profile.

Kiniksa continues to enroll patients in the Phase 3 portion of the Phase 2/3 clinical trial of mavrilimumab in severe COVID-19 pneumonia and hyperinflammation.

 

Unmet Need

Corticosteroids are the mainstay for the treatment of GCA, but approximately 50% to 70% of patients are corticosteroid refractory or corticosteroid dependent. Long-term administration of corticosteroids carries significant morbidity, especially in an elderly population such as in those with GCA. The FDA recently approved an inhibitor of IL-6 activity as an adjunct to a corticosteroid taper for the treatment of GCA; however, IL-6 production is downstream of GM-CSF and does not address all of the underlying causes of inflammation.

Photo of doctors working on tablets

Explore Our Pipeline

We are intent on developing an array of innovative therapies that answer the many and varied needs of patients.